Bausch + Lomb Corporation (BLCO) Stock Price & How to Invest
Last updated July 2026
Short answer
BLCO is Bausch + Lomb, a pure-play global eye-health company (contact lenses, lens care, dry-eye and surgical products) that returned to solid revenue growth in early 2026 while still carrying meaningful debt and an unresolved separation from majority owner Bausch Health. It is a turnaround-and-catalyst story rather than a steady compounder, so the investment case hinges on margin expansion sticking and the ownership overhang clearing.
BLCO stock price
As of 2026-07-20, Bausch + Lomb Corporation (BLCO) last closed at $15.98, up 14.7% over the past year. Over the past 52 weeks it has traded between $13.50 and $18.60.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Bausch + Lomb Corporation's investor relations page. Walnut is informational, not investment advice.
What does Bausch + Lomb Corporation (BLCO) do?
Bausch + Lomb is one of the oldest and best-known names in eye health, operating across three segments: Vision Care (roughly 57% of sales, spanning contact lenses like Biotrue and lens-care solutions plus consumer eye drops such as LUMIFY and PreserVision supplements), Pharmaceuticals (around 25%, led by the dry-eye drug MIEBO and international brands), and Surgical (about 18%, including intraocular lenses, phacoemulsification systems and cataract and retina instruments). Full-year 2025 revenue reached roughly $5.1 billion, and the company sells into the structurally growing markets of an aging population, rising myopia and expanding cataract volumes.
The investment picture is a mix of genuine operating improvement and unresolved corporate complexity. Q1 2026 revenue grew about 9% year over year to roughly $1.24 billion with adjusted EBITDA nearly doubling, prompting management to raise full-year guidance. At the same time, Bausch + Lomb remains roughly 88% owned by heavily indebted parent Bausch Health, whose long-delayed separation (via spin-off or outright sale) continues to cap the valuation. Layered on top are the residual effects of the 2025 enVista intraocular-lens recall and the company's own leverage, making this a name where the story matters as much as the numbers.
What's driving Bausch + Lomb Corporation (BLCO)?
1. Margin and EBITDA expansion
After years of underearning, Bausch + Lomb has been driving structural cost changes and pricing discipline. Q1 2026 adjusted EBITDA rose roughly 59% year over year, and management raised full-year adjusted EBITDA guidance toward the $1.01 to $1.06 billion range, signaling that the profitability inflection may be durable rather than a one-off.
2. Pharmaceuticals and MIEBO ramp
The pharmaceuticals segment posted the fastest growth in early 2026, led by the dry-eye drug MIEBO and international brands. Dry-eye disease is a large, underserved market, and continued MIEBO uptake gives the company a branded growth engine to offset slower U.S. generics.
3. Secular eye-care demand and surgical recovery
An aging global population, rising rates of myopia and growing cataract-surgery volumes support steady demand across contact lenses and surgical devices. The enVista intraocular-lens franchise returned to full production and reached pre-recall sales levels by late 2025, restoring its role in the premium IOL segment.
4. Separation catalyst from Bausch Health
Bausch Health still owns the large majority of BLCO and has explored both a spin-off and a sale for years. A clean separation, if it clears solvency hurdles, could remove the control discount and let BLCO trade closer to eye-care peers, though timing remains uncertain.
What are the risks to Bausch + Lomb Corporation (BLCO)?
The dominant overhang is Bausch Health's roughly $20 billion of consolidated debt and the repeatedly delayed separation, which caps BLCO's valuation and creates forced-seller and solvency-test risk. Bausch + Lomb carries its own meaningful leverage (several billion dollars of debt), so rising rates or slower EBITDA growth would pressure the balance sheet. The 2025 enVista recall, tied to toxic anterior segment syndrome, is estimated to weigh on 2026 revenue by roughly $78 million and could linger as a brand and litigation risk. The company remains net-loss-making on a GAAP basis, and competition from far larger and better-capitalized rivals like Alcon, Johnson & Johnson and CooperVision is intense across every segment.
How is Bausch + Lomb Corporation (BLCO) valued? (approximate, July 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Bausch + Lomb Corporation's investor relations page or your broker.
- Revenue (TTM): ~$5.2B
- FY2026 revenue guidance: ~$5.42B to $5.52B
- Q1 2026 revenue: ~$1.24B (+9% YoY)
- FY2026 adj. EBITDA guidance: ~$1.01B to $1.06B
- Q1 2026 net loss: ~$71M (narrowed from ~$212M)
- Enterprise value: ~$10B
BLCO is not yet consistently GAAP-profitable, so investors lean on adjusted EBITDA and revenue growth rather than earnings multiples. Eye-care peers such as Alcon and The Cooper Companies have traded near 18 to 20 times EV/EBITDA, versus a lower multiple for BLCO that reflects the Bausch Health control discount and leverage. Closing that gap depends heavily on the separation resolving and margins continuing to expand.
Who competes with Bausch + Lomb Corporation (BLCO)?
Contact lenses and vision care
Alcon, CooperVision (The Cooper Companies) and Johnson & Johnson Vision are the leading contact-lens and lens-care rivals, all larger and financially stronger, competing directly with Biotrue, Renu and Bausch + Lomb's lens portfolio.
Surgical and ophthalmic devices
Alcon, Johnson & Johnson (surgical vision), Carl Zeiss Meditec and Hoya compete in intraocular lenses, phacoemulsification systems and cataract and retina surgical equipment, where scale and physician relationships matter.
Eye pharmaceuticals
AbbVie (Allergan), Novartis and other branded and generic drugmakers compete in dry-eye and prescription eye drops, the market MIEBO addresses, alongside pressure from U.S. generic entrants.
How to invest in Bausch + Lomb Corporation (BLCO)
There are three common ways to get BLCO exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so BLCO sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where BLCO fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Bausch + Lomb Corporation (BLCO)
BLCO offers exposure to secular eye-care demand with improving fundamentals, but the Bausch Health control overhang and leverage keep it a higher-variance, situation-driven name.
More on Bausch + Lomb Corporation (BLCO)
Whether BLCO is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is BLCO a buy?, and where the stock could go from here in the BLCO stock forecast.
For income investors, whether BLCO pays a dividend and how the payout looks is covered in does BLCO pay a dividend?
Build a basket around BLCO with Walnut
Use Bausch + Lomb Corporation as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What does Bausch + Lomb (BLCO) do?
+
It is a global eye-health company selling contact lenses, lens-care solutions and consumer eye drops (Vision Care), prescription eye medicines like the dry-eye drug MIEBO (Pharmaceuticals), and cataract, retina and other surgical devices including intraocular lenses (Surgical).
Is BLCO profitable?
+
BLCO is growing revenue and adjusted EBITDA quickly, but it still reports GAAP net losses. Q1 2026 revenue rose about 9% to roughly $1.24 billion while the net loss narrowed to about $71 million from roughly $212 million a year earlier.
Why does BLCO trade at a discount to eye-care peers?
+
Bausch + Lomb is roughly 88% owned by heavily indebted parent Bausch Health, whose long-delayed separation and about $20 billion of consolidated debt create a control overhang and forced-seller risk that peers such as Alcon and CooperVision do not carry.
What is the Bausch Health separation about?
+
Bausch Health has tried since 2020 to fully separate its majority stake in BLCO through a spin-off or sale. Progress has been complicated by the parent's debt load and the need to pass a solvency test, leaving the timing and outcome uncertain.
What was the enVista recall?
+
In 2025 Bausch + Lomb voluntarily recalled certain enVista intraocular lenses after reports of toxic anterior segment syndrome tied to a raw material from a vendor. Production later resumed, and enVista IOL sales returned to pre-recall levels by late 2025, though estimated revenue impact runs into the tens of millions in 2026.
Who are BLCO's main competitors?
+
Key rivals include Alcon, CooperVision, Johnson & Johnson Vision, Carl Zeiss Meditec and Hoya in lenses and surgical devices, plus AbbVie (Allergan) and Novartis in eye pharmaceuticals. Most are larger and less leveraged than Bausch + Lomb.
What are the biggest risks with BLCO?
+
The main risks are the Bausch Health debt and separation overhang, BLCO's own leverage, continued GAAP losses, residual effects and possible litigation from the enVista recall, and intense competition from larger, better-funded eye-care companies.
How does BLCO fit a thematic portfolio?
+
BLCO can serve as an eye-health or aging-population healthcare exposure with a turnaround and catalyst angle. Because of the ownership overhang and leverage it tends to be higher-variance than pure-play peers, which some investors weigh when sizing it. Walnut is not an investment adviser.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Bausch + Lomb Corporation's investor relations page or your broker before making investment decisions.